(CercleFinance.com) – Teva and Medincell announced on Wednesday positive results for their phase 3 clinical trial dedicated to their long-acting experimental treatment against schizophrenia.
The study, which aimed to measure the effectiveness of a monthly long-acting subcutaneous injection of olanzapine, met its primary endpoint in all groups that received doses of TV-‘749 compared to the group placebo.
The Israeli generic and its French partner even report ‘remarkable’ reductions from a clinical point of view and statistically significant in the total score on the positive and negative symptoms scale (PANSS), an assessment tool widely used for gauge the severity of schizophrenia symptoms.
There are currently no options for treating schizophrenia with long-acting olanzapine without the risk of post-injection delirium/sedation syndrome (PDSS).
As such, the development of new innovative long-acting therapeutic options could better meet the needs of these patients, who often experience episodes of relapse.
Teva and Medincell say additional efficacy and safety results from the phase 3 study are expected to be presented at a scientific conference later this year.
An estimated 3.5 million people are currently diagnosed with schizophrenia in the United States alone.
Medincell announced this morning that it had requested the suspension of the trading of its shares on the Paris Stock Exchange pending the publication of a press release.
The resumption of negotiations on its securities must take place tomorrow at the opening of the markets.